- Lannett (NYSE:LCI) has entered into a future exclusive supply and distribution agreement for Levothyroxine Sodium Tablets USP of Cediprof, Inc., a wholly owned subsidiary of Neolpharma Pharmaceutical Group.
- Under the agreement, Lannett will commence U.S. distribution no later than August 1, 2022. The Company will make an upfront payment of $20M and will receive a portion of the net profits.
- The term of the agreement is 10 years, which begins upon commencement of distribution. Other terms were not disclosed.
- Shares are up 2% premarket.